DUBLIN–(BUSINESS WIRE)–The “Duchenne
Muscular Dystrophy Treatment Market – Growth, Trends, and Forecast (2019
– 2024)” report has been added to ResearchAndMarkets.com’s
offering.
The Duchenne muscular dystrophy treatment market is expected to register
a CAGR of nearly 47.6% during the forecast period, 2019-2024.
The propelling factors for the growth of the Duchenne muscular dystrophy
(DMD) treatment market include the rising disease burden of Duchenne
muscular dystrophy, increasing investments in biopharmaceutical R&D to
release novel disease therapies, and increasing awareness campaigns for
DMD.
Currently, there is an increase in the number of clinical trials for
testing the future treatment for Duchenne muscular dystrophy. The only
accepted pharmacological therapy for the treatment of DMD is
corticosteroid-based anti-inflammatory treatment.
The rising prevalence of chronic diseases, such as cardiovascular and
neurovascular diseases, and arthritis, and increasing healthcare
insurance coverage are the major factors likely to accelerate the growth
of the market. The pharmaceutical drug discovery and development have
also grown rapidly in the past few years.
As there have been great breakthroughs in technology in the last few
years that may facilitate research processes and as the explosion of
science in understanding the causes of diseases has made target
selection more rational than ever, almost all major companies are now
concentrating on R&D, which is likely to have a major impact on the
market in the coming years.
Furthermore, with increasing awareness among people and with the
government’s urgency for the treatment of the disease, there is a big
opportunity for the companies to conduct their trails and for new drugs
launches, due to which, the market is expected to grow in the coming
years.
Key Market Trends
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to
Grow Fastest During the Forecast Period
Corticosteroids are the only known pharmacological treatment for DMD and
help to suppress muscle inflammation. This treatment is being limited by
its inadequate therapeutic efficacy, and considerable side effects, and
hence, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to
reduce the inflammation of muscles. The nonsteroidal anti-inflammatory
drugs are expected to witness a CAGR of 49.2% over the forecast period.
However, other therapies and treatments include stem cell therapy,
repurposing drugs, anti-fibrotics, myostatin inhibition, gene editing
(CRISPR/Cas9), etc. Currently, prednisone/prednisolone and deflazacort
have been used for the treatment of Duchenne muscular dystrophy, which
is expected to drive the growth of the market, over the forecast period.
North American Region holds the Largest Market Share of the Market
Currently and is Believed to Follow the Same Trend Over the Forecast
Period
North America dominates the global Duchenne muscular dystrophy market,
due to new product innovations, high healthcare expenditure, and
government awareness programs.
The United States has dominated the regional market and is projected to
maintain its lead, owing to the rising disease incidence and anticipated
launch of promising pipeline candidates. In addition, the market is
expected to grow with the increasing clinical trials around the world,
especially in the United States and Europe.
Competitive Landscape
With increasing campaigns and awareness programs, the number of patients
is expected to come down, and hence, many companies are conducting
campaign programs that help to improve focus on medicines for DMD
treatment. There are also very few companies for new drug research for
rare diseases because it needs bigger funds.
Therefore, the market is not well established in many other therapeutic
areas. However, it is expected to experience high growth and expand
during the forecast period.
Topics Covered
1 Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)
4.2.2 Increasing Investments in Biopharmaceutical R&D to Release Novel
Disease Therapies
4.2.3 Increasing Awareness Campaigns for DMD
4.3 Market Restraints
4.3.1 Lack of Standardization to Measure Clinical Efficacy Across All
Stages of DMD
4.3.2 Stringent Regulatory Framework with High Product Cost Burden
4.4 Porter’s Five Forces Analysis
5 Market Segmentation
5.1 By Therapeutic Approach and Treatment Type
5.1.1 Molecular-based Therapies
5.1.1.1 Mutation Suppression
5.1.1.2 Exon Skipping
5.1.2 Steroid Therapy
5.1.2.1 Corticosteroids
5.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
5.1.4 Other Therapeutic Approaches and Treatment Types
5.2 By End User
5.2.1 Hospitals/Clinics
5.2.2 Ambulatory Centers
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle East & Africa
5.3.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 BioMarin
6.1.2 Bristol-Myers Squibb Company
6.1.3 Fibrogen Inc.
6.1.4 Eli Lilly and Company
6.1.5 Nobelpharma Co. Ltd.
6.1.6 NS Pharma Inc.
6.1.7 Pfizer Inc.
6.1.8 PTC Therapeutics
6.1.9 Santhera Pharmaceuticals
6.1.10 Sarepta Therapeutics
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/research/wjfvvk/global_duchenne?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs , Musculoskeletal
Disorders Drugs